Key Insights The considerable ownership by individual investors in Huber+Suhner indicates that they collectively have a...

Most readers would already be aware that Huber+Suhner's (VTX:HUBN) stock increased significantly by 63% over the past...

Key Insights Huber+Suhner's estimated fair value is CHF114 based on 2 Stage Free Cash Flow to Equity Huber+Suhner's...

The cider brand has added a high-contrast NaviLens QR code to its cans.

BioReference health, JPMorgan Chase and an Italian fashion retailer are making the job cuts amid market uncertainty

Novartis will acquire Tourmaline Bio for $48 per share, valuing the New York-based biopharmaceutical company at $1.4 billion on a fully diluted basis, the Swiss pharma giant said on Tuesday. Tourmaline is focused on developing pacibekitug, a promising targeted therapy with the potential to reduce systemic inflammation, as a treatment option for atherosclerotic cardiovascular disease, Novartis said in a statement. With the deal, Novartis will acquire a Phase III-ready asset that will complement its existing cardiovascular disease portfolio, it said.

Novartis will acquire Tourmaline Bio for $48 per share, valuing the New York-based biopharmaceutical company at $1.4 billion on a fully diluted basis, the Swiss pharma giant said on Tuesday. Tourmaline is focused on developing pacibekitug, a promising targeted therapy with the potential to reduce systemic inflammation, as a treatment option for atherosclerotic cardiovascular disease, Novartis said in a statement. With the deal, Novartis will acquire a Phase III-ready asset that will complement its existing cardiovascular disease portfolio, it said.

Huber+Suhner AG's ( VTX:HUBN ) robust earnings report didn't manage to move the market for its stock. Our analysis...

Huber+Suhner AG ( VTX:HUBN ) came out with its half-yearly results last week, and we wanted to see how the business is...